What is Sarilumab?

Sarilumab is a fully human anti-interleukin 6 (IL-6) receptor monoclonal IgG1 antibody that binds to membrane-bound and soluble IL-6 receptor forms, thereby blocking the cis- and trans-inflammatory signaling cascades of IL-6. SalirumabbySanofi and Regeneron Developed by Pharmaceuticals, it was approved by the U.S. Food and Drug Administration (FDA) in May 2017 and subsequently by the European Union in June 2017 for the treatment of moderate to severe rheumatoid arthritis (RA) in combination with methotrexate.

The treatment of moderate to severe rheumatoid arthritis, a chronic inflammatory disease characterized by polyarthritis, is challenged by the variable response of each patient. Subcutaneous injection of salirumab has been shown to reduce acute phase reactant levels and improve symptoms of clinically moderate to severe rheumatoid arthritis. Following a single subcutaneous dose, salirumab shows good absorption in patients with rheumatoid arthritis, with maximum serum concentrations occurring after 2-4 days. For the dosing regimen of 150 mg every two weeks, the AUC, Cmin and Cmax of salivolumab were 202±120mg.day/L, 6.35±7.54mg/L and 20.0±9.20mg/L respectively.

The patent drug of Salirutumab is a new type of drug for treating diseases. It is not yet on the market in China, and therefore it is not covered by medical insurance. Salirumab The common dosage form of the original drug is injection, which has been marketed overseas. The European version of specifications200mg*2 bottles is priced around 17,500 per box (The price may fluctuate due to exchange rates). There are currently no generics of Salirumab produced in other countries.